MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Managing Paravalvular Leaks After TAVR
Will next-generation percutaneous valve technologies address this current limitation?
By Satpal S. Arri, BSc, MRCP, and David Hildick-Smith, MD, FRCP
British Bifurcation Coronary Study Compares Stenting Strategies
March 1, 2010—David Hildick-Smith, MD, et al have published findings from BBC ONE (British Bifurcation Coronary Study) online ahead of print in Circulation.
Systematic Two-Stent Culotte Strategy Studied in Large-Caliber Side Branch Bifurcations
September 27, 2016—David Hildick-Smith, MD, et al published findings from the EBC TWO study online ahead of print in Circulation: Cardiovascular Interventions.
UK Enrollment Commences in International REDUCE Study of Gore's Helex Septal Occluder
November 1, 2011—Gore & Associates (Flagstaff, AZ) announced the beginning of United Kingdom enrollment in the multicenter, international REDUCE clinical study, which includes up to 50 investigational sites in the United States and Europe.
PRIMA Examines Effect of Percutaneous PFO Closure on Migraine
September 16, 2014—Findings from the PRIMA trial—evaluating whether percutaneous patent foramen ovale (PFO) closure is effective in reducing migraine headaches compared to medical treatment—were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Structural Disease Update
By Ted E. Feldman, MD, MSCAI, FACC, FESC
UK's Stroke Research Network Adopts Gore REDUCE Clinical Study
June 19, 2012—Gore & Associates (Flagstaff, AZ) announced that the United Kingdom's National Institute for Health Research Stroke Research Network (NIHR SRN) has adopted the Gore REDUCE clinical study to help encourage patient recruitment across England.
Initial Results Presented for St. Jude Medical's Amplatzer Amulet LAA Closure Device
November 2, 2016—Initial results from the Amulet Observational Study were presented at TCT 2016, the 28th annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC.
New Sizes and Expanded Indications for Medtronic's Resolute Onyx DES Introduced in Europe
February 1, 2016—Medtronic plc announced the European CE Mark approval and the commercial launch of an expanded size matrix of the next-generation Resolute Onyx drug-eluting stent (DES) that is now available in 4.5- and 5-mm diameter sizes.
